ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Wednesday.

Several other analysts have also commented on the company. BidaskClub lowered ANI Pharmaceuticals Inc Common Stock from a “hold” rating to a “sell” rating in a report on Tuesday. Canaccord Genuity set a $75.00 price objective on ANI Pharmaceuticals Inc Common Stock and gave the company a “buy” rating in a report on Thursday, August 16th. Cantor Fitzgerald set a $74.00 price objective on ANI Pharmaceuticals Inc Common Stock and gave the company a “buy” rating in a report on Tuesday, August 7th. Finally, Zacks Investment Research lowered ANI Pharmaceuticals Inc Common Stock from a “buy” rating to a “hold” rating in a report on Tuesday, July 10th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. ANI Pharmaceuticals Inc Common Stock presently has a consensus rating of “Hold” and a consensus price target of $72.67.

ANIP traded down $0.99 during trading on Wednesday, hitting $54.40. The company’s stock had a trading volume of 70,900 shares, compared to its average volume of 106,248. The company has a current ratio of 3.84, a quick ratio of 2.89 and a debt-to-equity ratio of 1.08. ANI Pharmaceuticals Inc Common Stock has a twelve month low of $49.25 and a twelve month high of $74.70. The firm has a market cap of $664.09 million, a P/E ratio of 15.07 and a beta of 2.75.

ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP) last issued its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported $1.13 EPS for the quarter, missing the consensus estimate of $1.34 by ($0.21). ANI Pharmaceuticals Inc Common Stock had a net margin of 0.06% and a return on equity of 27.76%. The business had revenue of $47.27 million during the quarter, compared to analyst estimates of $50.70 million. equities research analysts forecast that ANI Pharmaceuticals Inc Common Stock will post 4.49 EPS for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Mount Yale Investment Advisors LLC purchased a new position in shares of ANI Pharmaceuticals Inc Common Stock in the first quarter valued at approximately $102,000. Piedmont Investment Advisors LLC purchased a new position in shares of ANI Pharmaceuticals Inc Common Stock in the second quarter valued at approximately $140,000. Sei Investments Co. lifted its position in shares of ANI Pharmaceuticals Inc Common Stock by 56.9% in the first quarter. Sei Investments Co. now owns 2,252 shares of the specialty pharmaceutical company’s stock valued at $131,000 after acquiring an additional 817 shares in the last quarter. Millennium Management LLC purchased a new position in shares of ANI Pharmaceuticals Inc Common Stock in the fourth quarter valued at approximately $210,000. Finally, Crossmark Global Holdings Inc. purchased a new position in shares of ANI Pharmaceuticals Inc Common Stock in the second quarter valued at approximately $235,000. 60.68% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Inc Common Stock Company Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.

Featured Story: Hedge Funds Explained

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for ANI Pharmaceuticals Inc Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.